CD14 and neoplasm: The percentages of IL-10+CD14+CD169+ circulating monocytes and TIMs in total CD14+CD169+ cells from CRC patients were significantly higher than that from the non-tumor subjects (3.79% vs. 0.76%, P<0.0001 for circulating monocytes; 7.12% vs. 1.23%, P<0.0001 for TIMs.